Citadel Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Citadel Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-592	Closed	-$9K	–	15311
2021 Q4	$9K	Buy	592 +60	+11%	+$1.42K	﹤0.01%	13676
2021 Q3	$16K	Sell	532 -304	-36%	-$8.58K	﹤0.01%	13664
2021 Q2	$28K	Sell	836 -124	-13%	-$4.62K	﹤0.01%	13498
2021 Q1	$40K	Buy	960 +500	+109%	+$31.1K	﹤0.01%	12988
2020 Q4	$28K	Buy	460 +305	+197%	+$33K	﹤0.01%	10725
2020 Q3	$21K	Buy	+155	New	+$25.9K	﹤0.01%	9855
2020 Q2	–	Sell	-46	Closed	-$7K	–	10833
2020 Q1	$7K	Buy	+46	New	+$14.1K	﹤0.01%	9465
2019 Q3	–	Sell	-110	Closed	-$67K	–	10041
2019 Q2	$67K	Buy	+110	New	+$67.5K	﹤0.01%	8655
2019 Q1	–	Sell	-49	Closed	-$18K	–	10151
2018 Q4	$18K	Buy	+49	New	+$26.3K	﹤0.01%	8795

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Addison Advisors Middlebury, Vermont $452M AUM 14.62% 1-Year Est. Return

Citadel Advisors's NBRV Position: Q2 2023 in Review

Citadel Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2023, closing a stake of 11,607 shares — an estimated $20.1K sold.

Citadel Advisors first reported a position in NBRV in Q1 2018 and held it in 18 quarters. The position peaked at $172K in Q2 2020. 9 funds tracked by Wall St. Rank hold NBRV as of Q2 2023.

Citadel Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 11,607 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2023, an estimated $20.1K.
Citadel Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2018 and held it in 18 quarters.
Citadel Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $172K in Q2 2020.
9 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.